MDPI and ACS Style
Del Vecchio, M.; Chiarion Sileni, V.; Quaglino, P.; Rinaldi, G.; Minisini, A.; Troiani, T.; Consoli, F.; Sponghini, A.; Banzi, M.; Morelli, M.F.;
et al. The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study. Cancers 2023, 15, 1980.
https://doi.org/10.3390/cancers15071980
AMA Style
Del Vecchio M, Chiarion Sileni V, Quaglino P, Rinaldi G, Minisini A, Troiani T, Consoli F, Sponghini A, Banzi M, Morelli MF,
et al. The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study. Cancers. 2023; 15(7):1980.
https://doi.org/10.3390/cancers15071980
Chicago/Turabian Style
Del Vecchio, Michele, Vanna Chiarion Sileni, Pietro Quaglino, Gaetana Rinaldi, Alessandro Minisini, Teresa Troiani, Francesca Consoli, Andrea Sponghini, Maria Banzi, Maria Francesca Morelli,
and et al. 2023. "The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study" Cancers 15, no. 7: 1980.
https://doi.org/10.3390/cancers15071980